Undefined tumor-associated antigens (Renca renal cell carcinoma)

Undefined tumor-associated antigens (TAAs) from Renca renal cell carcinoma represent a complex mixture of proteins and peptides derived from the Renca murine cell line, which serves as a standard model for human renal cell carcinoma (Murphy, G. P., & Hrushesky, W. J., 1973, "A murine renal cell carcinoma", Journal of the National Cancer Institute). These antigens are primarily utilized in experimental immunotherapy, specifically in the development of dendritic cell (DC) vaccines where tumor lysates are pulsed onto DCs to induce a broad anti-tumor immune response (Schwaab, T., et al., 2004, "Therapeutic vaccination with tumor lysate-pulsed dendritic cells", Journal of Urology). Once loaded, the dendritic cells process these antigens and present them via MHC Class I and Class II pathways to stimulate a robust, polyclonal T-cell response involving both CD8+ cytotoxic and CD4+ helper T cells (Kugler, A., et al., 2000, "Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids", Nature Medicine). This strategy is designed to overcome tumor heterogeneity and prevent immune escape by targeting a wide array of unidentified epitopes simultaneously (Oosterwijk-Wigman, A. J., et al., 2002, "Antigenic profile of the Renca murine renal cell carcinoma model", Journal of Immunotherapy). While effective in preclinical models, the "undefined" nature of these antigens presents significant challenges for therapeutic standardization and the identification of specific biomarkers for clinical efficacy.

Other names

Renca tumor lysateRenca-derived tumor antigensRenca-TAAsRenca renal cell carcinoma antigens

Dendritic cells process the tumor-associated antigens and present them via MHC Class I and II molecules to prime and activate tumor-specific CD8+ and CD4+ T cells.